DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Globotriaosylceramide
Globotriaosylceramide
Sphingolipid Metabolism Diseases ⁎ Thomas Kolter, Konrad Sandhoff
The Neutral Glycosphingolipid Globotriaosylceramide Promotes Fusion Mediated by a CD4-Dependent CXCR4-Utilizing HIV Type 1 Envelope Glycoprotein
Occurrence of Sulfatide As a Major Glycosphingolipid in WHHL Rabbit Serum Lipoproteins1
Ceramide and Related Molecules in Viral Infections
Gb3 and Lyso-Gb3 and Fabry Disease
VIEW Open Access T-Cell Metabolism in Autoimmune Disease Zhen Yang1, Eric L Matteson2, Jörg J Goronzy1 and Cornelia M Weyand1*
The Kidney in Fabry Disease: More Than ª the Author(S) 2016 DOI: 10.1177/2326409816648169 Mere Sphingolipids Overload Iem.Sagepub.Com
Disorders of Sphingolipid Synthesis, Sphingolipidoses, Niemann-Pick Disease Type C and Neuronal Ceroid Lipofuscinoses
Mechanism of Secondary Ganglioside and Lipid Accumulation in Lysosomal Disease
Novel Intrinsic and Extrinsic Approaches to Selectively Regulate
Review Article Ganglioside Biochemistry
Low Frequency of Fabry Disease in Patients with Common Heart Disease
Fabry Disease: Molecular Basis, Pathophysiology, Diagnostics and Potential Therapeutic Directions
Inherited Metabolic Disorders Involving The
Sulfatide Analysis by Mass Spectrometry for Screening Of
Molecular Pathways and Respiratory Involvement in Lysosomal Storage Diseases
Sphingolipids (GSL) Takes Place at the Intracellular Membranes of Endoplas- Mic Reticulum and the Golgi Apparatus in Eukaryonic Cells
Treatment of Lysosomal Storage Disorders: Focus on the Neuronal Ceroid-Lipofuscinoses
Top View
Abnormal Sphingolipid World in Inflammation Specific for Lysosomal
Polar Lipid Remodeling and Increased Sulfatide Expression Are Associated
Lysosomal Storage Diseases: Diagnostic Confirmation and Management of Presymptomatic Individuals Raymond Y
The Role of Globotriaosylceramide in Internalization and Functions Of
Sphingolipids and Kidney Disease: Possible Role of Preeclampsia and Intrauterine Growth Restriction (IUGR)
Lysosomal Storage Disease Overview
Lyso-Glycosphingolipids: Presence and Consequences
Lysosomal Storage Diseases ª the Author(S) 2014 DOI: 10.1177/2326409813517663 Iem.Sagepub.Com
Metabolism of Glycosphingolipids and Their Role in the Pathophysiology of Lysosomal Storage Disorders
Characterization of a New Model of GM2-Gangliosidosis (Sandhoff's Disease) in Korat Cats
Glycosphingolipid Depletion in Fabry Disease Lymphoblasts with Potent Inhibitors of Glucosylceramide Synthase
Fabry Disease and Incidence of Cancer Sarah Bird1, Efthymios Hadjimichael2, Atul Mehta1, Uma Ramaswami1 and Derralynn Hughes1*
Download Product Insert (PDF)
Changes in Plasma and Urine Globotriaosylceramide Levels Do Not Predict Fabry Disease Progression Over 1 Year of Agalsidase Alfa
Lysosomal Lipid Storage Diseases
EGL Test Description
Lipid Metabolism Biofilesonline Biofilescontents Your Gateway to Biochemicals and Reagents for Life Science Research Introduction 3
One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease
Lysosomal Storage Diseases Carlos Ferreira George Washington University
Lysosomal Storage Diseases
The Role of GLYCOSPHINGOLIPIDS and SPHINGOLIPIDS in Rare Lysosomal Storage Diseases and Other Rare Diseases1–8
Mechanisms of Mitochondrial Dysfunction in Lysosomal Storage Disorders: a Review
Gangliosides in Podocyte Biology and Disease
Characterization of Glycolipids from the Gastric
Infusion of -Galactosidase a Reduces Tissue Globotriaosylceramide
Exploiting the Potential of Drosophila Models in Lysosomal Storage Disorders: Pathological Mechanisms and Drug Discovery